Miller & Martin Represents Mayne Pharma in New Equity Investment in HedgePath Pharmaceuticals
May 20, 2015
On May 18, 2015, Mayne Pharma Group Limited announced that it has finalized an agreement with U.S.-based HedgePath Pharmaceuticals, Inc. (HPPI) to invest U.S. $2.5M cash in return for additional common stock in HPPI and warrants to purchase HPPI common stock. This funding will be used to accelerate HPPI's clinical development program using Mayne Pharma's patented oral formulation of Itraconazole, known as SUBA-Itraconazole, to treat certain cancers.
The Miller & Martin team representing Mayne Pharma in the transaction includes: Joe DeLisle, Ashley Halfman, Chris Henderson, Jonathan Edwards, Jimmy Daniel, Bill DuPre, Mike Marshall, Jim Tramonte and Frank Williams. Miller & Martin was first introduced to Mayne Pharma by Australian law firm Minter Ellison in 2012, to represent the company in the acquisition of Metrics, Inc., a pharmaceuticals company based in North Carolina. Miller & Martin and Minter Ellison are both members of the World Law Group, an exclusive network of 56 member firms with nearly 20,000 lawyers serving clients from more than 325 offices in 70 countries.